ClinicalTrials.gg
RecruitingNCT07256301Updated May 14, 2026

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 1 interventional study of EA5 in PNH - Paroxysmal Nocturnal Hemoglobinuria, sponsored by Shanghai Lanyi Therapeutics Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Shanghai Lanyi Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jan 2024, registered Nov 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Planned enrollment
35th of 47
24 · median 40
Started
2024
with 11 others
Phase 1
13 of 51
5 open now
Primary completion
2026-08
later than 10 of 28 live
Registered
42nd of 51
by date

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 35th largest by planned enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 1, reaches primary completion later than 10 of the 28 other live ones, and was the 42nd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Read the detailed description

This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). The study plans to enroll 24-26 PNH patients. The primary objective is to assess the incidence and severity of adverse events (AEs) from baseline to Week 14.The treatment period is divided into a Loading Phase (Day 1 to Day 14) and a Maintenance Phase (Day 15 to Day 85). During the maintenance phase, patients will be assigned to one of three dose cohorts: Cohort 1/Cohort 1' (900 mg, IV, Q4W), Cohort 2/Cohort 2' (1200 mg, IV, Q4W), and Cohort 3 (1400 mg, IV, Q4W). Cohorts 1-3 are for patients previously naive to complement inhibitor therapy, while Cohorts 1'-2' are for patients recently naive to complement inhibitor therapy.

03

Conditions studied

  • PNH - Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • EA5、PNH、Paroxysmal Nocturnal Hemoglobinuria、C5 complement inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥18 years.
  • Body weight between 40 kg and 100 kg (inclusive) at screening.
  • Patients diagnosed with PNH, confirmed by flow cytometry demonstrating a PNH clone size (glycosylphosphatidylinositol-anchored protein-deficient granulocytes or monocytes) of ≥10% in peripheral blood, and meeting one of the following criteria:

    • a) Previously naive to complement inhibitor therapy; or
    • b) Previously treated with a complement inhibitor, which has been discontinued for ≥5 half-lives prior to screening.
  • Lactate dehydrogenase (LDH) level ≥1.5 times the (ULN) at screening.
  • Presence of one or more of the following PNH-related signs or symptoms within 3 months prior to screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia ( \<10 g/dL), history of major thrombotic event (including thrombosis), dysphagia, or erectile dysfunction; or a history of packed red blood cell (pRBC) transfusion due to PNH.
  • Vaccination against Neisseria meningitidis(serogroups A, C, W, Y) within \<3 years prior to the initiation of study treatment; OR if not previously vaccinated, receipt of the meningococcal vaccine (MPV-ACYW) at least 14 days prior to the first dose of the product. If the vaccine is administered within 14 days before dosing, antibiotic prophylaxis must be provided until 2 weeks post-vaccination.
  • Vaccination against Streptococcus pneumoniaeaccording to national vaccination recommendations (e.g., ACIP guidelines). OR if not previously vaccinated, receipt of the pneumococcal vaccine at least 14 days prior to the first dose of the investigational product. If the vaccine is administered within 14 days before dosing, antibiotic prophylaxis must be provided until 2 weeks post-vaccination.
  • For patients receiving concomitant therapies (e.g., , , iron supplements, anticoagulants, erythropoiesis-stimulating agents): the dose must have been stable for ≥28 days prior to the first dose of the investigational product.
  • count ≥30 × 10\^9/L at screening (without transfusion support within 7 days), and (ANC) ≥0.5 × 10\^9/L (without short-acting granulocyte colony-stimulating factor (G-CSF) within 14 days or long-acting G-CSF within 28 days).
  • Adequate liver function, defined as (ALT) ≤3 × ULN, OR both direct and alkaline phosphatase (ALP) ≤2 × ULN at screening.
  • Adequate renal function, defined as serum creatinine ≤2.5 × ULN and an estimated ≥30 mL/min as calculated by the Cockcroft-Gault formula.
  • Male subjects must agree to use effective (including vasectomy, abstinence, or condom) from screening until 6 months after the final study intervention. Women of (WOCBP) must have a negative blood pregnancy test at screening and baseline. During the study and for 6 months thereafter, all subjects and their partners must agree to use effective contraceptive measures (Note: contraceptive measures include both pharmacological and non-pharmacological methods).
  • Ability to understand the procedures and methods of the study, willingness to provide written , and commitment to strictly adhere to the clinical study protocol to complete the study.

Exclusion criteria

Exclusion Criteria:

  • History of bone marrow transplantation.
  • History of Neisseria meningitidisinfection within 6 months prior to screening and before the first dose.
  • Known or suspected immunodeficiency (e.g., history of frequent or recurrent infections).
  • Known or suspected hereditary complement deficiency.
  • Evidence of active tuberculosis (TB) within 6 months prior to screening, or a history of active TB without having completed an appropriate, documented course of treatment; OR chest X-ray (posteroanterior and lateral) or CT scan findings during the 3 months prior to screening or during the screening period that suggest the presence of active TB infection.
  • History of major surgery (Grade 3 or 4 surgery) within 3 months prior to the first dose.
  • Presence of an disease, OR use of systemic /immunomodulatory agents (including, but not limited to, methotrexate, cyclosporine, mycophenolate, tacrolimus, penicillamine, sulfasalazine, hydroxychloroquine, azathioprine, cyclophosphamide) for the treatment of inflammatory diseases within 12 weeks or 5 half-lives (whichever is longer) prior to screening.
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to the first dose; OR requirement for hospitalization or intravenous antibiotic therapy for an infection between 28 days prior to screening and the first dose; OR requirement for oral antibiotic therapy for an infection between 14 days prior to screening and the first dose.
  • Occurrence of fever (≥38°C) within 7 days prior to the first drug administration.
  • Administration of any within 1 month prior to the first dose.
  • History of within 5 years prior to screening and before the first dose, with the following exceptions: patients with any malignancy that has been treated with curative intent and who have been disease-free and off treatment for >5 years prior to the first dose may be enrolled. Patients with a history of basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situof the cervix that has been cured with no evidence of recurrence at any time prior to the first dose may be enrolled. Patients with a history of low-grade, early-stage prostate cancer (Gleason score ≤6, Stage 1 or 2) not requiring treatment at any time prior to the first dose may be enrolled.
  • History of allergy to any component of EA5, including a history of to human, humanized, or murine monoclonal antibodies, or known hypersensitivity to any of the product.
  • Any to receiving the meningococcal vaccination and/or antibiotic prophylaxis (e.g., beta-lactam antibiotics, ciprofloxacin) as required by the study protocol.
  • Participation in another interventional therapeutic clinical trial involving an drug or receipt of any experimental therapy within 3 months (or within 5 half-lives of the investigational agent, whichever is longer) prior to screening.
  • History of drug abuse within 12 months prior to screening, as judged by the investigator.
  • Alcohol abuse, or regular alcohol consumption exceeding 14 units per week within 6 months prior to screening (1 unit of alcohol ≈ 360 mL of beer, or 45 mL of 40% spirits, or 150 mL of wine).
  • Splenectomy performed within ≤6 months prior to screening.
  • Positive for virus (HCV) antibody at screening (except for those with a negative HCV RNA result), positive for (HIV) antibody, positive for anti-Treponema pallidumantibody (TP-Ab) (except for those with a negative RPR or TRUST test), OR positive for virus (HBV) surface antigen (HBsAg) (except for those with an HBV DNA level ≤1000 IU/mL).
  • History of or ongoing cryoglobulinemia at the time of screening.
  • History of myelodysplastic syndromes (MDS), with a Revised International Prognostic Scoring System (IPSS-R) risk category of Intermediate, High, or Very High.
  • Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in the trial.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1 and Cohort 1'

    Participants were administered EA5 900 milligram (mg) on Day 1 and Day 8, EA5 900 mg on Day 15, and then EA5 900 mg every 4 weeks for 2 doses.

    Biological: EA5

  • Experimental
    Cohort 2 and Cohort 2'

    Participants were administered EA5 900 milligram (mg) on Day 1 and Day 8, EA5 1200 mg on Day 15, and then EA5 1200 mg every 4 weeks for 2 doses.

    Biological: EA5

  • Experimental
    Cohort 3

    Participants were administered EA5 900 milligram (mg) on Day 1 and Day 8, EA5 1400 mg on Day 15, and then EA5 1400 mg every 4 weeks for 2 doses.

    Biological: EA5

Interventions

  • BiologicalEA5

    All treatments were given as IV infusions.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to Week 14

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of EA5

    Blood samples were collected for analysis of Cmax

    Time frame: Baseline up to Week 14

  2. Time To Maximum Observed Serum Concentration (Tmax) of EA5

    Blood samples were collected for analysis of Tmax

    Time frame: Baseline up to Week 14

  3. Area Under The Serum Concentration Versus Time Curve From Time Zero To The Time of The Last Quantifiable Concentration (AUC0-t) of EA5

    Blood samples were collected for analysis of AUC0-t

    Time frame: Baseline up to Week 14

  4. Area Under The Serum Concentration Versus Time Curve From Time Zero (Dosing) To Infinity (AUCinf) of EA5

    Blood samples were collected for analysis of AUCinf

    Time frame: Baseline up to Week 14

  5. Terminal Elimination Rate Constant (λz) of Serum EA5

    Blood samples were collected for analysis of λz

    Time frame: Baseline up to Week 14

  6. Terminal Elimination Half-life (t½) of Serum EA5

    Blood samples were collected for analysis of t½

    Time frame: Baseline up to Week 14

  7. Total Clearance (CL) of EA5

    Blood samples were collected for analysis of CL

    Time frame: Baseline up to Week 14

  8. Percent Change From Baseline in Free Complement Component 5 (C5)

    Blood samples were collected for analysis of free C5 concentrations.

    Time frame: Baseline up to Week 14

  9. Percent Change From Baseline in Total Complement C5

    Blood samples were collected for analysis of total C5 concentrations.

    Time frame: Baseline up to Week 14

  10. Percent Change From Baseline in determination of terminal complement activity in serum

    Blood samples were collected for analysis of determination of terminal complement activity

    Time frame: Baseline up to Week 14

  11. Percentage of Participants With Positive Anti-Drug Antibody (ADA)

    Blood samples were collected to evaluate antibody response through development of ADAs.

    Time frame: Baseline up to Week 14

07

Study locations

2 of 2 sites recruiting
  • The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
    Tianjin, Tianjin Municipality 300020, China
    Recruiting
    • Fengkui Zhang, Dr. · Contactzhfk@hotmail.com · +86-022-23909999
    • Fengkui Zhang, Dr. · Principal investigator
  • The First Affiliated Hospital, Zhejiang University School of Medicine, Chengzhan Campus
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • Hongyan Tong, Dr. · Contacthongyantong@yahoo.com.cn · +86-0571-56181000
    • Hongyan Tong, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2026, 31 months after the start.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 1, 2025
StartActual
Jan 3, 2024
Primary completionEst.
Aug 31, 2026
CompletionEst.
Oct 30, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07256301
Lead sponsor
Shanghai Lanyi Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Dec 1, 2025
Start date
Jan 3, 2024
Primary completion
Aug 31, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
May 14, 2026

Study contacts

Fengkui zhang, Dr.
Contact
zhfk@hotmail.com
+86-022-23909999
Fengkui Zhang, Dr.
principal investigator · The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
Hongyan Tong, Dr.
principal investigator · The First Affiliated Hospital, Zhejiang University School of Medicine, Chengzhan Campus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EA5

Start the discussion